A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson’s Disease
Principal Investigator: Sotirios Parashos, MD, PhD
Study sponsor: Inhibikase Therapeutics, Inc.
Location: Struthers Parkinson’s Center – Golden Valley
Purpose of study: The goal of the study is to see if IkT-148009 can keep Parkinson’s Disease from getting worse.
Inclusion Criteria:
-Be 30-75 years old
-Be diagnosed with Parkinson’s Disease
-Not be receiving any anti-parkinsonian therapy
Study Contact:
Rebekah Heisick
(952) 993-5903
Rebekah.Heisick@ParkNicollet.com
For more information, please visit the study’s clinicaltirals.gov site at:
https://clinicaltrials.gov/study/NCT05424276
A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study in Parkinson’s Disease Patients With Dyskinesia to Assess the Efficacy and Safety/Tolerability of Fixed Dose Combinations of JM-010 and its Individual Components BK-JM-201
Principal Investigator: Sotirios Parashos, MD, PhD
Study sponsor: Bukwang Pharmaceutical Co., Ltd.
Location: Struthers Parkinson’s Center – Golden V alley
Phase of Study: II
Purpose of study: This is a study for Parkinson’s disease patients with dyskinesia to assess the efficacy and safety/tolerability of fixed dose combinations of JM-010 and its individual components.
Patients must:
– Be 18 to 80 years of age
– Be diagnosed with Parkinson’s disease (PD) and taking a stable dose of levodopa 3 to 6 times daily
– Have muscle twitches and twisting movement (dyskinesia) that is moderately to completely disabling (more than one hour per day)
Study Contact:
Rebekah Heisick
(952) 993-5903
Rebekah.Heisick@parknicollet.com
For more information, please visit the study’s clinicaltirals.gov site at:
https://clinicaltrials.gov/study/NCT04377945
Intranasal Insulin in Parkinson’s Disease (INI-PD)
Principal Investigator: Julia Johnson, MD
Study Sponsor: Struthers’s Parkinson’s Center – Saint Paul, HealthPartners Neuroscience Center
Location: Struthers’s Parkinson’s Center – Saint Paul
Purpose of study: The purpose of this study is to investigate the safety and tolerability of insulin delivered as a nasal spray (intranasally) when administered to individuals with Parkinson’s disease (PD). In addition, the effect of intranasal insulin on motor function, cognitive function and mood in PD will be investigated.
There will be a total of three in-person study visits and at least two phone visits over the course of 2 months at the HealthPartners Neuroscience Center located at 295 Phalen Boulevard, St. Paul, MN 55130. Each participant is on the study medication or placebo for 3 weeks. A designated care partner/family member may be needed to be present for all 3 visits and to help with dosing every day, 1-2 times daily, for 3 weeks.
Inclusion Criteria:
– Diagnosis of Parkinson’s Disease
– Have previously undergone a brain CT or MRI as part of receiving a Parkinson’s diagnosis
–If needed, have a dedicated family member of caregiver who can attend all study visits
Exclusion Criteria:
–Currently taking insulin for diabetes or are allergic to insulin
–History of other central nervous system disorders
Study Contact:
(651) 495-6363
ClinicalTrials@HealthPartners.com
For more information, please visit the study’s clinicaltirals.gov site at:
https://clinicaltrials.gov/study/NCT04251585
Parkinson’s Foundation PD GENEration Genetic Registry
Principal Investigator: Martha Nance, MD
Study sponsor: Parkinson’s Foundation
Location: Struthers Parkinson’s Center
Purpose of study: Purpose: to help improve our understanding of Parkinson’s Disease and help participants and their clinicians understand their genetic status to improve care, which includes determining eligibility for clinical trial participation. Study includes a baseline visit (in-person or by video) and a genetic counseling visit (by video, phone, or in-person) to discuss your test results with the study doctor.
Inclusion Criteria:
– Diagnosis, or probable diagnosis, for Parkinson’s Disease.
– Capacity to give full informed consent.
– Participant must have residential address in MN or Wisconsin.
Exclusion Criteria:
– Received a blood transfusion within the past 3 months.
– Received a bone marrow transplant within the past 5 years.
– Active blood cancer, such as lymphoma or leukemia.
– Under the age of 18.
Study Contact
Rebekah Heisick
(952) 993-5903
Rebekah.Heisick@parknicollet.com
For more information, please visit the study’s clinicaltirals.gov site at:
https://clinicaltrials.gov/study/NCT04994015
Randomized, Double-blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Lenrispodun as Adjunctive Therapy in the Treatment of Patients with Motor Fluctuations due to Parkinson’s Disease
Principal Investigator: Sotirios Parashos, MD, PhD
Study Sponsor: Intra-Cellular Therapies, Inc.
Location: Struthers Parkinson’s Center – Golden Valley
Purpose of study: The purpose of this study is to compare the efficacy of lenrispodun 30 mg administered once daily as adjunctive therapy to stable doses of existing levodopa therapy with that of placebo as adjunctive therapy to stable doses of existing levodopa therapy in patients with motor fluctuations due to Parkinson’s disease.
Patients must:
-Be 40-80 years old
-Be diagnosed with Parkinson’s Disease
-Have a clinically meaningful response to levodopa
Study Contact:
Rebekah Heisick
(952) 993-5903
Rebekah.Heisick@parknicollet.com
For more information, please visit the study’s clinicaltrials.gov site at: https://clinicaltrials.gov/study/NCT05766813
Role of Attention in Gait and Balance in Parkinson’s Disease
Principal Investigator: Sotirios Parashos, MD, PhD
Study sponsor: Parkinson’s Foundation
Location: Struthers Parkinson’s Center
Purpose of study: People diagnosed with Parkinson’s Disease, even in the early course of the disease, have cognitive deficits without dementia. Cognitive deficits have been correlated with gait and balance difficulties. The purpose of this study is to determine the impact of attention on gait and balance in individuals with early Parkinson’s Disease without dementia.
This study will compare those with Parkinson’s disease to those without Parkinson’s disease; thus, healthy volunteers (spouses/partners/friends/loved ones) 40 years of age or older are welcome to participate but not required. Participation in this study will involve one visit.
Inclusion Criteria:
– Able to walk 6 minutes without use of a walker or wheelchair (cane or walking sticks are okay).
– Those with Parkinson’s disease, age 30 or older at time of diagnosis.
– Those without Parkinson’s disease, age 40 or older at time of testing.
– If on medication for Parkinson’s disease and/or memory enhancing medication, should be on a stable regimen for at least 30 days
prior to participation.
Exclusion Criteria:
– Unable to walk without use of a walker or wheelchair for 6 minutes.
– Late-stage Parkinson’s disease.
Study Contact
Rebekah Heisick
(952) 993-5903
Rebekah.Heisick@parknicollet.com
